首页|期刊导航|中国药房|血凝酶类药物临床合理应用专家共识

血凝酶类药物临床合理应用专家共识OA

Expert consensus on the clinical rational use of hemocoagulase drugs

中文摘要英文摘要

目的 制定《血凝酶类药物临床合理应用专家共识》,为血凝酶类药物(以下简称"血凝酶")的临床合理应用及规范化管理提供决策依据.方法 由北京医院(国家老年医学中心)牵头,联合国内临床药学、骨科、神经外科、急诊科、妇产科、消化科等领域的34位专家,围绕血凝酶的10个临床实践问题,系统梳理国内外的研究证据与临床实践经验,经充分讨论后形成该共识.结果 该共识共形成24条推荐意见,包括血凝酶的给药途径与适用范围、不同给药途径下的使用剂量、用药监测和管理、不良反应管理、特殊人群用药监测与管理、血凝酶与常见止血药物和/或止血材料联合使用、注射途径使用血凝酶减少围手术期出血、局部应用途径使用血凝酶减少围手术期出血、血凝酶减少非手术相关出血的应用、血凝酶减少创伤相关出血的应用10个方面.结论 该共识为血凝酶的临床应用提供了系统化的循证指导,有助于规范临床实践、优化给药方案、保障用药安全,从而改善患者的治疗结局.

OBJECTIVE To formulate Expert Consensus on the Clinical Rational Use of Hemocoagulase Drugs,thereby providing a decision-making basis for the rational clinical application and standardized management of hemocoagulase drugs(hereinafter referred to as"hemocoagulase").METHODS Led by Beijing Hospital(National Center for Gerontology),in collaboration with 34 experts in clinical pharmacy,orthopedics,neurosurgery,emergency medicine,obstetrics and gynecology,gastroenterology,and other relevant fields,the consensus was developed through a systematic review of domestic and international research evidence and clinical practice experience pertaining to 10 clinical practice issues concerning hemocoagulase,followed by in-depth discussion.RESULTS A total of 24 recommendations were formulated,covering the following 10 aspects:the routes of administration and scope of application;dosage under different routes of administration;medication monitoring and management;adverse reaction management;medication monitoring and management in special populations;the combined use of hemocoagulase with common hemostatic drugs and/or hemostatic materials;the use of injectable hemocoagulase to reduce perioperative bleeding;the use of locally applied hemocoagulase to reduce perioperative bleeding;the application of hemocoagulase in reducing non-surgery-related bleeding;and the application of hemocoagulase in reducing trauma-related bleeding.CONCLUSIONS This consensus provides systematic,evidence-based guidance for the clinical application of hemocoagulase,facilitating the standardization of clinical practice,the optimization of dosing regimens,and the assurance of medication safety,thereby improving patient treatment outcomes.

赵紫楠;宋再伟;张宇迪;赵飞;胡欣;金鹏飞;中国医药教育协会老年药学专业委员会;中国老年保健医学研究会药事管理与药学创新分会;北京医师协会临床药师分会

北京医院(国家老年医学中心)药学部,老年疾病国家临床医学研究中心,国家卫生健康委老年医学重点实验室,中国医学科学院老年医学研究院,北京 100730北京大学第三医院药学部,北京 100191首都医科大学附属北京妇产医院妇产科,北京 100006北京医院(国家老年医学中心)药学部,老年疾病国家临床医学研究中心,国家卫生健康委老年医学重点实验室,中国医学科学院老年医学研究院,北京 100730北京医院(国家老年医学中心)药学部,老年疾病国家临床医学研究中心,国家卫生健康委老年医学重点实验室,中国医学科学院老年医学研究院,北京 100730北京医院(国家老年医学中心)药学部,老年疾病国家临床医学研究中心,国家卫生健康委老年医学重点实验室,中国医学科学院老年医学研究院,北京 100730

医药卫生

血凝酶类药物合理用药规范化管理专家共识

hemocoagulase drugsrational drug usestandardized managementexpert consensus

《中国药房》 2026 (17)

2213-2223,11

首都卫生发展科研专项(No.首发2024-1-4052)

10.6039/j.issn.1001-0408.2026.17.01

评论